As a Co-founder of End the Legacy, a nonprofit dedicated to supporting individuals at risk of Genetic ALS/FTD and their families, I have witnessed firsthand the profound impact of ALS/FTD. My commitment to making a difference led me to join Coya Therapeutics, a clinical-stage company focused on developing first-in-class therapeutics for ALS and other neurodegenerative diseases, where I serve as the VP of Operations and Patient Advocacy.In my role at Coya Therapeutics, I am actively involved in the commercialization of a groundbreaking therapy for ALS patients and those affected by other neurodegenerative diseases. My work extends beyond the corporate realm, as I continue to collaborate with End the Legacy, acting as a vital link between patients seeking a cure and what I believe to be the forefront company in this field.Driven by a passion for creating positive change and fostering hope, I am dedicated to bridging the gap between innovative research and the individuals and families affected by ALS. Together with End the Legacy and Coya Therapeutics, I am committed to advancing the fight against ALS and making a meaningful impact on the lives of those touched by this challenging disease.